Chronic Hand Eczema Market Outlook to 2028: Global Assessment, Insights, Epidemiology, Drugs, Competition -

DUBLIN--()--The "Chronic Hand Eczema Market Insights, Epidemiology and Market Forecast-2028" drug pipelines has been added to's offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Chronic Hand Eczema in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chronic Hand Eczema from 2017 to 2028 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Study Period: 2017-2028

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Companies Mentioned

  • Basilea Pharmaceuticals
  • LEO Pharma
  • Asana BioSciences

Chronic Hand Eczema Epidemiology

According to this research, total prevalent population of Chronic Hand Eczema (CHE) in 7 major markets was found to be 4,229,215 in 2017.

The Chronic Hand Eczema (CHE) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology {Total prevalent cases, gender-specific cases, diagnosed cases, severity-specific diagnosed prevalent cases [mild to moderate, moderate, moderate to severe, severe], subgroup-specific diagnosed prevalent cases [Irritant contact eczema, Atopic hand eczema, Allergic contact eczema, Dishydrotic hand eczema, Hyperkeratotic rhagadiform hand eczema, Fingertip eczema] and age-specific diagnosed prevalent cases [20-29 yrs., 30-49 yrs., 50-69 yrs., 70 and above]} scenario of Chronic Hand Eczema in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028

Chronic Hand Eczema Drug Chapters

This segment of the Chronic Hand Eczema report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases

At present, the therapeutic market size of Chronic Hand Eczema is includes topical corticosteroids, calcineurin inhibitors, phototherapy and other radiation therapies. For the relapse or recurrent conditions, systemic therapies are the only available option. These includes short-term oral corticosteroids, immunosuppressant such as azathioprine, methotrexate, cyclosporine, mycophenolate mofetil and oral retinoids. There is no approved systemic therapy available in the US and Japan for the treatment of corticosteroid resistant CHE. However, alitretinoin is the only drug that has been specifically developed for the indication of CHE and got approval in multiple European countries, Canada, South Korea and Israel for the treatment of severe chronic hand eczema (CHE), refractory to treatment with potent topical corticosteroid. Besides all these treatment options, the market consists of various unmet needs including limited availability of appropriate therapeutic treatment, poor understanding of disease in chronic state and lack of awareness.

To counter the current unmet needs, the market is expected to have better treatment options for CHE. With the continuous efforts in research and development, few companies are developing therapies such as LEO Pharma, Japan Tobacco, Asana Biosciences, Afecta Therapeutics, NUVO research and Aralez Pharmaceuticals. Detailed chapter for upcoming therapies like Delgocitinib (LEO Pharma); ASN002 (Asana Biosciences) have also been covered in the report.

Chronic Hand Eczema Market Outlook

According to this research, the market of Chronic Hand Eczema in 7MM was found to be USD 1,226.71 million in 2017.

The Chronic Hand Eczema market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight

Chronic Hand Eczema Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions


  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition


  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This report will help to develop Business Strategies by understanding the trends shaping and driving Chronic Hand Eczema market
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Hand Eczema market
  • To understand the future market competition in the Chronic Hand Eczema market

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900